SWOG clinical trial number
SWOG-8049

The Treatment of Resected, Poor Prognosis Malignant Melanoma: Stage I: Surgical Excision Versus Surgical Excision + Vitamin A

Closed
Phase
Published
Abbreviated Title
The Treatment of Resected, Poor Prognosis Malignant Melanoma: Stage I: Surgical Excision Versus Surgical Excision + Vitamin A
Activated
07/29/1981
Closed
03/15/1987

Research committees

Melanoma

Publication Information Expand/Collapse

2002

Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model.

RJ Tuthill;JM Unger;PY Liu;LE Flaherty;VK Sondak American Journal of Clinical Pathology 118(4):504-511

1997

Adjuvant therapy for melanoma.

VK Sondak;JA Wolfe Current Opinion in Oncology 9:189-204

1995

Tumor infiltrating lymphocytes (TILs) instage I cutaneous melanoma: A Southwest Oncology Group study.

RJ Tuthill;DJ Rector;VK Sondak;PY Liu;FL Meyskens International Academy of Pathology Book of Abstracts :51A(#284)

1994

Randomized trial of vitamin A versus observation as adjuvant therapy in high risk primary malignant melanoma: A Southwest Oncology Group study

FL Meyskens;PY Liu;RJ Tuthill;VK Sondak;WS Fletcher;WR Jewell;W Samlowski;SP Balcerzak;DJ Rector;RD Noyes;JJ Costanzi Journal of Clinical Oncology 12(10):2060-2065

1990

Observation versus oral vitamin A for adjuvant treatment of stage I cutaneous melanoma.

FL Meyskens Jr.;J Costanzi;K Kopecky;P Goodman Adjuvant Therapy of Cancer 6:593-597

1988

A randomized phase III trial of high dose vitamin A versusplacebo for stage I malignant melanoma.

MS Tallman;FR Appelbaum;K Kopecky;D Amos;S Dahlberg;M Grever;C Coltman, Jr;ED Thomas ASCO 7:247(#955)

Other Clinical Trials

SWOG Clinical Trial Number
S2000

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases
Research Committee(s)
Melanoma
Activated
09/23/2020
Accrual
100%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6174

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Research Committee(s)
Melanoma
Activated
10/01/2018
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6141

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Research Committee(s)
Melanoma
Activated
09/10/2015
Open
Phase